The treatment for infected wounds


(57) Abstract:

The invention relates to medicine, in particular to the surgery and the result they have proved. To enhance antibacterial activity and expansion of the spectrum of antibacterial action antibacterial contains streptocid and nitazol, the condensation product of propylene oxide and ethylene mol.m 13000 (proxanol is chosen-268), 1,2-propylene glycol (PEO-400) in the following ratio, wt. % : streptocid 2 - 6; nitazol 1 - 3; proxanol is chosen-268 20 - 30; 1,2-propylene glycol 37,5 - 42,7; PEO-400 18,0 - 37,5. table 2.

The invention relates to medicine, in particular to surgery and combustology.

Closest to the claimed object antibacterial substance of choice for the local treatment of wounds infected by Pseudomonas aeruginosa in Association with other microbes is the ointment mafenide acetate, which is the acetate salt of 4-aminoethylethanolamine. This drug chemical structure closest to sulfanilamide, in particular the streptocide, and selected as a prototype.

This is known ointments, wt.%: Mafenide acetate 10.0 polyethylene oxide-1500 40.0 polyethylene oxide-400 34,5 distilled Water 15.0 Sodium sulfate 0,5

The ointment mafenide what about it is necessary to apply very high concentration of 10%. Because of this, when applying the ointment on the burn or wound surface patients are effects local irritation, pain, burning. In severe pain even recommended the appointment of analgesics. In addition, you can priyanie dressing with ointment to the wound, which reduces the concentration of mafenide acetate directly on the wound surface, and in some cases may interfere with wound drainage and cause bleeding and damage to the wound surface when changing the dressing. For these reasons, 10% ointment mafenide acetate proved to be unsuitable for application to large areas of wounds and burns.

The aim of the invention is the enhancement of antibacterial activity and expansion of the spectrum of antibacterial action.

This goal is achieved by the fact that medicine as an antibacterial substances contains streptocid and nitazol, as polymer is a condensation product of propylene oxide and ethylene mol.m.13000 (proxanol is chosen-268), as a two - component solvent mixture of 1,2-propylene glycol and polyethylene oxide mol.m. 400 (PEO-400) in the following ratio, wt.%: Streptocide 4-6 Nitazol 1-3 proxanol is chosen-268 20-30 1,2-propylene glycol 37,5-42,7 PEO-400 37,5-18,3

P R I m e R s. In the Ola-268 and dissolution in the melt nitazola and streptocide, then gave to cool the composition to the 25aboutWith constant stirring. Ointment 100 g was packaged in bottles of dark glass.

The dynamics of the treatment of purulent-inflammatory process in the local treatment stratonicea rabbits are presented below.

Source on the 7th day after infection, animals bacteria: the wounds 4x4 - 5x6 see Around the edges of wounds hyperemic edematous skin. Edges of wounds nekrotizirovanne. Wounds filled with viscous blue-green purulent content. Made of surgical treatment of wounds. Imposed headbands with stratonicea. Inoculation of pus and esecanna necrotic tissue revealed Pseudomonas aeruginosa in the amount of 108-10101 g of tissue.

I-th day after the treatment of animals: the wounds 4x4 - 5x6 see Redness and swelling of the underlying tissue decreased. The wound edges and some parts of the wound depth infiltrated, there is necrotic tissue. Pus viscous, blue-green. Produced debridement. The bandage was applied with stratonicea. When planting necrotic tissue revealed Pseudomonas aeruginosa 106-108microbial cells in 1 g of tissue.

3rd day after treatment animals: rabbits active, good appetite, the wounds 3x4 - 4x4 1,

5th day after treatment animals: wounds dry 3x4 see the edges of the wound pink granulation Only in the depth of the wound serous secretion. Change bandages with stratonicea. Sowing tissue from the wound revealed Pseudomonas aeruginosa in the amount of 102-103microbial cells in 1 g of tissue.

7 days after treatment animals: wounds the size of 2-3 cm, dry, covered with crust. The entire surface wounds covered with pink granulation. At the edges of wounds observed epithelialization. Change bandages with stratonicea. When sowing tissue from the wound revealed a single colony of Escherichia coli.

10th day after treatment of animals: the wound dry, kapitalizirovana on a large surface area. Pseudomonas aeruginosa from fabrics not planted.

Thus, the claimed composition does not lose its activity when heavyline and exhibits antibacterial properties in experiments in vivo, reducing the level of bacterial contamination of the wound already to the third day of treatment 5 orders of magnitude; On the 5th day of treatment of microbial infection of wounds by Pseudomonas aeruginosa becomes below a critical level of development of inflammatory process (1051 g of tissue), and to the 7-10 day she wound almost no planted.

Antibacterial ointments are presented in table.1 and 2.

FOR the TREATMENT of INFECTED wounds, containing an antibacterial substance and a hydrophilic ointment base, characterized in that as an antibacterial substances it contains streptocid and nitazol and the base contains proxanol is chosen-268 (the condensation product of propylene oxide and ethylene (mol. m 13000), 1,2-propylene glycol and PEO-400 with a ratio of components, wt.%:

Streptocide 4 - 6

Nitazol 1 - 3

Proxanol is chosen-268 20 - 30

1,2-Propylene glycol 37,5 - 42,7

PEO-400 18,3 - 37,5


Same patents:

The invention relates to 7-examinerlawrence heterocyclic Amida - analogues of prostaglandins, which are receptor antagonists AND thromboxane a2(THA2or combined receptor antagonists AND thromboxane a2(thromboxane synthetase inhibitors, and are used, for example, in the treatment of thrombotic disease and/or vascular spasm: have a long duration of action

The invention relates to a new di-tert-butylaniline derivative used for the treatment of inflammatory processes, as well as caused by ischemia cell damage
The invention relates to medicine

The invention relates to medicine, in particular to intensive therapy for the treatment of traumatic and hemorrhagic shock

The invention relates to the field of medicine and relates to an anti-inflammatory composition and method of its production

FIELD: medicine; pharmaceutical engineering.

SUBSTANCE: pharmaceutical composition COMPRISES 5-(2-pyrazinyl)-4-methyl-1,2-dithyol -3-thion (oltipraze) and dimethyl-4,4'-dimetoxi-5,6,5',6'-dimethylene-dioxybiphenyl-2,2' dicarboxilate (DDB) as the main components. Oltipraze: DDB proportion is preferentially equal to 50-1:1-50, the most preferential being 5:1.

EFFECT: enhanced effectiveness of treatment.

6 cl, 6 dwg, 9 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with antiviral preparations that contain aliphatic alcohol C21-C28 in combination with either nucleoside or nucleotide analog or phosphoformic acid in pharmaceutically acceptable carrier. It is necessary to mention that n-docosanol is considered to be a preferable aliphatic alcohol. Concentration of aliphatic alcohol C21-C28 corresponds to 0.05% to 40% by weight. Concentration of either nucleoside or nucleotide analog or phosphoformic acid corresponds to 0.1% to 10% by weight. The innovation, also, deals with the ways to treat viral infections due to applying such compositions. Aliphatic alcohols C21-C28 synergistically intensify antiviral activity of nucleoside analogs directed against replication of several herpetic viruses and that of cow's pox.

EFFECT: higher efficiency of inhibition.

28 cl, 13 dwg, 21 ex, 6 tbl

FIELD: medicine, obstetrics, gynecology, mammology.

SUBSTANCE: method involves administration of alcohol-air mixture into cyst cavity wherein the amount of air and alcohol is similar and represents 40-60% of the content volume evacuated from the cyst cavity. Invention promotes to prophylaxis of diseases relapses and prevention of iatrogenic complications associated with carrying out this procedure. Invention can be used for treatment of patients with cystic mactopathy.

EFFECT: improved method for treatment.

2 tbl

FIELD: thoracic surgery and pulmonology.

SUBSTANCE: method comprises complex therapy utilizing ecdysterone-containing preparation, namely 0.005-0.01% ecdysterone solution prepared by dissolving ecdysterone in mixture of equal portions of 70% alcoholic tinctures of calendula and eucalyptus. Preparation is administered orally in dose of 30-40 drops before meal.

EFFECT: activated formation of antibodies, function of phagocytes and T cells, protein synthesis processes, including surfactant synthesis, and stabilized alveolocyte membranes.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation should be fulfilled due to performing sclerotherapy with 96%-ethanol under ultrasound control at the dosage of 0.5-1 ml/ml of nodal volume in case of nodal neoplasms and 3-5 ml in case of cystic neoplasm after liquid aspiration. Moreover, a day before each course of sclerotherapy one should introduce Movalis for 5-10 d once daily after meals. The course of sclerotherapy should be started with introducing 96%-ethanol, then 8-10 d later it is necessary to introduce benzyl peniccilin sodium salt at the dosage of 0.5-1 ml/ml of nodal volume in case of nodal neoplasm, and 0.5 ml after liquid aspiration - in case of cystic neoplasm. The innovation enables to decrease side manifestations of complex therapy performed due to decreasing the quantity of injections.

EFFECT: higher efficiency of therapy.

1 cl, 4 ex

FIELD: medicine, proctology.

SUBSTANCE: the present innovation deals with introducing a sclerosing preparation consisting of equal parts of 96% alcohol and 2% lidocain at the quantity of 2-4 ml, for all fissures it is necessary to inject 10 ml 0.5%-novocain solution and 2 ml solcoseryl or actovegin, then one should change the direction to move a needle towards coccyx towards sphincter's external diameter to introduce 5 ml 0.5%-Novocain solution and, not shifting a needle, one should introduce a sclerosing preparation. The innovation enables to conduct simultaneously the following procedures: anesthesia, the rupture of adhesions, blocking painful and sensitive branches of pudendal nerve that innervate ulcerous area that leads then to decreased pain syndrome, decreased sphincter's spasm and better ulcer's healing.

EFFECT: higher efficiency of sclerotherapy.

2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: claimed agent contains as active ingredient quarternary ammonium compound and/or N,N-bis(3-aminopropyl)-dodecylamine and/or polyhexamethylene guanidine derivative; non-ionic surfactant, alcohol, urea, synthetic C12-C14- or C10-C16-fatty acid alkylamides; chelator, as well as dye, odorant, and water in specific ratio (mass %).

EFFECT: environmentally friendly anti-infective agent of high antimicrobial action, excellent washing properties and high effectiveness in low concentration.

3 tbl, 13 ex, 3 cl

FIELD: organic chemistry, pesticides.

SUBSTANCE: claimed composition represents mixture of carvacrol and thymol compounds with salt of transition metal, namely zinc, wherein carvacrol and thymol compound/zinc ratio is from 60:40 to 65:35. Also described is pesticide composition containing mixture of carvacrol and thymol compounds with salt of transition metal, namely zinc, and at least one carrier, wherein weight ratio of carvacrol to thymol is 10:1. Claimed method for parasite controlling includes step of composition blending with carrier and application thereof onto target area.

EFFECT: composition for pest controlling and prevention of contamination with pests such as insect, mite, fungi or parasites.

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to ointment used in treatment of scars by external using on a patient body. Ointment for treatment of scars comprises wax, vegetable oil, heparin, lydaze, glycerol and dimethylsulfoxide in the following ratio of components per 100 g: wax, 13-15 g; heparin, 5000-10000 U; lydaze, 64-128 U; dimethylsulfoxide, 10-15 ml; glycerol, 10-15 ml, and vegetable oil, the balance. Invention provides enhancing effectiveness in treatment of patients and the absence of adverse complications.

EFFECT: improved, enhanced and valuable medicinal properties of ointment.

1 tbl, 3 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with medicinal treatment of ischemic variant of primary glaucoma in case of stable normalization of intraocular pressure (IOP) in patients with myopic refraction. For this purpose, it is necessary to carry out electromagnetic impact successively onto cerebral orbital, temporal and occipital areas, carotid sinuses of cervical autonomic plexus, and, also, one should additionally inject gliatilin per 1.0 in combination with instillations of 0.5%-betaxolol solution per 2 drops twice daily into ocular conjunctival cavity. Therapy should last for 10 d at repeating the course once or twice annually. The method provides stable normalization of IOP, improves cerebral and orbital hemodynamics and stabilization of visual functions.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to biologically active compounds. Agent represents 3,6-dioxocyclohexa-1,4-diene-1,2,4,5-tetrasulfonate sodium. The new agent elicits antioxidant properties and therefore it can be used in food industry, in pharmaceutical compositions and cosmetic products. Also, the new agent elicits antiviral activity owing to it can be used as both the independent medicinal agent and in compositions with other preparations used for treatment of viral infections.

EFFECT: expanded assortment of medicinal agents and antioxidants, realization of indicated prescription.

1 tbl, 8 dwg

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to new biphenylsulfonylcyanamides of the formula (I): wherein R1 means: 1. (C1-C8)-alkyl; 4. -CnH2n-nn-Y wherein nn = 0 or 2 and n = 0-4, and n is not 0 or 1 if nn = 2; 5. CnH2n-nn-Y wherein nn = 0 or 2 and n = 1-4, and n is not 1 if nn = 2, and 1 hydrogen atom in bivalent residue CnH2n-nn is substituted with amino-group or NR(22)R(23); R2 means: 2. (C1-C)-alkyl; 4. (C2-C12)-alkenyl; 5. (C2-C8)-alkynyl; 6. -CnH2n-nn-Z wherein nn = 0 or 2; n = 0-4, and n is not or 1 if nn = 2; 7. -CnH2n-nn-Z wherein nn = 0 or 2; n = 1-4, and n is not 1 if nn = 2, and 1 hydrogen atom in bivalent residue CnH2n-nn is substituted with a residue taken among a series: 1. phenyl; 3. NR(22)R(23); 5. COOR(16); R3 and R4 mean hydrogen atom; R5, R6 and R7 mean independently of one another hydrogen atom (H), (C1-C8)-alkyl; SO2-(C1-C4)-alkyl, F, Cl, Br, J, OR(10) wherein R(10) means hydrogen atom, (C1-C4)-alkyl that is substituted if necessary with methoxy- or ethoxy-group; R(9) means OR(13) wherein R(13) means hydrogen atom, H,(C1-C8)-alkyl;X means carbonyl group, -CO-CO- or sulfonyl group; Y and Z mean independently of one another: 1. phenyl, 1-naphthyl, 2-naphthyl; 2. one of residues determined in cl. 1 substituted with 1-5 similar or different residues taken among a series: phenyl, F, Cl, Br, J, CF3, SOqR(18), OR(16), NR(19)R(20), -CN, NO2, COR(9), or two residues form methylenedioxy-group; 3. furyl, thienyl, pyridyl, benzimidazolyl, indolyl, benzothiophenyl, dihydroquinazolinyl; 5. (C3-C10)-cycloalkyl wherein cyclopropyl, cyclopentyl, cyclohexyl and indalyl are preferable; 6. one of residues determined in cl. 5 substituted with phenyl; R(16) means: 1. hydrogen atom; 2. (C1-C4)-alkyl; 3. (C1-C4)-alkyl substituted with (C1-C4)-alkoxy-group; R(19) and R(20) mean independently: hydrogen atom (H), (C1-C4)-alkyl; R(22) and R(23) mean independently of one another hydrogen atom (H) or CO-OR(24) wherein R924) means -CnH2n-phenyl wherein n = 1-4; q = 2; and their physiologically acceptable salts. Compound of the formula (I) inhibit sodium-dependent chloride-bicarbonate exchange "NCBE".

EFFECT: improved preparing method, valuable medicinal properties of compounds.

4 cl, 2 tbl, 568 ex

FIELD: pharmaceutical industry, medicine.

SUBSTANCE: invention relates to new compounds of formula


wherein A and B are independently CH or CR3; X is C=O or (CR4aR4b)m, (m = 1 or 2); Y is S(O)n-R2 (n = 1 or 2), S(O)n-NR2R2, or S(O)n-OR2; N1 and N2 are nitrogen atoms; Q and R1 are independently 1) optionally substituted C1-C10-alkyl; 2) optionally substituted aralkyl containing C6-C10-aryl, attached to C1-C10-alkyl; 3) optionally substituted aralkenyl containing C5-C10-aryl, attached to C1-C10-alkenyl; 4) optionally substituted C6-C10-aryl; 5) optionally substituted aryl, containing 5-10 ring atoms, selected from carbon and sulfur; each R2 and R3 are hydrogen; R4a, R4b, R5, and R6, are independently hydrogen; R2 and R3 are independently hydrogen or C1-C6-alkyl; as well as acid and base additive salts thereof. Also disclosed are method for production of claimed compounds, pharmaceutical composition inhibiting serine protease enzymes and therapeutic method based thereon.

EFFECT: new compounds and pharmaceutical composition for thrombosis preventing or abnormal thrombosis treatment.

11 cl, 7 tbl, 15 ex